<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">YASUOKA, SHOTARO</style></author><author><style face="normal" font="default" size="100%">YUASA, TAKESHI</style></author><author><style face="normal" font="default" size="100%">OGAWA, MASAHIRO</style></author><author><style face="normal" font="default" size="100%">KOMAI, YOSHINOBU</style></author><author><style face="normal" font="default" size="100%">NUMAO, NOBORU</style></author><author><style face="normal" font="default" size="100%">YAMAMOTO, SHINYA</style></author><author><style face="normal" font="default" size="100%">KONDO, YUKIHIRO</style></author><author><style face="normal" font="default" size="100%">YONESE, JUNJI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5803-5809</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.13784</style></doi><volume><style face="normal" font="default" size="100%">39</style></volume><issue><style face="normal" font="default" size="100%">10</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Cabazitaxel (CBZ) is approved for docetaxel-resistant castration-resistant prostate cancer (CRPC). This retrospective study aimed at assessing the efficacy and prognostic markers of cabazitaxel treatment in Japanese CRPC patients. Patients and Methods: The medical records of 44 consecutive Japanese patients with CRPC who started cabazitaxel at our Institution between January 2011 and February 2019 were reviewed and statistically analysed. Results: The median follow-up period after cabazitaxel initiation was 13.2 [interquartile range (IQR)=6.9-21.5] months. The objective response rate, median progression-free survival period, and median overall survival period (OS) were 45.5%, 4.3 months, and 20.7 months, respectively. On multivariate analysis, higher prostate-specific antigen (PSA; &gt;100 ng/ml), lower haemoglobin (&lt;10 g/dl), and lower number of prior docetaxel therapy cycles (&lt;10) were predictors for shorter OS. Conclusion: Patients with anemia, high PSA, and lower number of docetaxel therapy cycles might have shorter survival period from introduction of cabazitaxel therapy. In addition, PSA decline might still be a useful indicator as a predictor of prognosis of the metastatic CRPC patients treated with cabazitaxel.</style></abstract></record></records></xml>